Full range of in vitro and in vivo protocols
Cellular toxicity in primary cell cultures and cell lines
Design and validation of novel bio-markers
Pharmacodynamic target identification and validation
Click here to request specific information
3A Laboratories develop novel drugs in Neuropathic Pain and Oncology
3A is developing novel molecules for use in neuropathic pain which is a debilitating condition affecting ~8% of the population. We work on the voltage-gated calcium channel in collaboration with other pre-clinical development organizations to generate a more efficient and safer medication for neuropathic pain. In addition, we are currently exploring the VGCC a2d-1 subunit as a tumor marker and therapeutic target for solid tumor indications.
